Perspective - Virology Research Journal (2023) Volume 7, Issue 2
Antiviral agents for emerging viral infections and targeting the immune system
Department of applied Cell Sciences, School of Advanced Technologies on Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Corresponding Author:
- Arasu Tamimi
Department of applied Cell Sciences
School of Advanced Technologies on Medicine
Tehran University of Medical Sciences, Tehran, Iran
Received: 22-Feb-2023, Manuscript No. AAVRJ-23-90738; Editor assigned: 23-Feb-2023, PreQC No. AAVRJ-23-90738(PQ); Reviewed: 08-Mar-2023, QC No. AAVRJ-23-90738; Revised: 13-Mar-2023, Manuscript No. AAVRJ-23-90738(R); Published: 18-Mar-2023, DOI:10.35841/AAVRJ-7.2.137
Citation: Tamimi A. Antiviral agents for emerging viral infections and targeting the immune system. Virol Res J. 2023;7(2):137
Emerging viral infections, such as COVID-19, pose significant public health threats worldwide. Antiviral agents are critical in treating and preventing the spread of these infections. Antiviral agents work by targeting the virus directly, preventing it from replicating, or indirectly by enhancing the host immune system to fight off the virus. This article will explore the use of antiviral agents for emerging viral infections, including their mechanisms of action and how they target the immune system.
Antiviral Agents for Emerging Viral Infections
Antiviral agents are drugs that specifically target viruses, inhibiting their replication and spread within the host. The primary targets of antiviral agents include viral proteins, enzymes, and receptors that are essential for the virus's survival and replication. There are several classes of antiviral agents, including nucleoside/nucleotide analogs, protease inhibitors, fusion inhibitors, and neuraminidase inhibitors .
Nucleoside/nucleotide analogs are synthetic compounds that mimic the structure of the nucleosides or nucleotides required for viral replication. They work by being incorporated into the viral genome during replication, causing errors in viral replication and preventing the virus from producing infectious particles. Examples of nucleoside/nucleotide analogs include acyclovir, ribavirin, and remdesivir. Protease inhibitors are drugs that target viral proteases, enzymes required for viral replication. By inhibiting the protease activity, these drugs prevent the virus from processing viral proteins into functional components for replication. Examples of protease inhibitors include lopinavir and ritonavir [2,3].
Fusion inhibitors and neuraminidase inhibitors are drugs that prevent the virus from entering or exiting host cells. Fusion inhibitors block the fusion of the viral and host cell membranes, preventing the virus from entering the cell. Neuraminidase inhibitors, such as oseltamivir, block the release of new viral particles from infected cells, preventing the spread of the virus.
Targeting the Immune System
In addition to targeting the virus directly, antiviral agents can also target the host immune system, which plays a critical role in fighting off viral infections. The immune system consists of various cells, such as T cells, B cells, and natural killer cells, that work together to identify and eliminate infected cells.
One way to target the immune system is by using immunomodulatory agents. These drugs work by regulating the immune response to viral infections, enhancing the immune system's ability to fight off the virus. For example, interferons are a group of proteins that are naturally produced by the immune system in response to viral infections. Interferons can stimulate the immune system to produce more immune cells and enhance their function, helping to fight off viral infections. Interferon therapy has been used to treat various viral infections, including hepatitis B and C, and some types of cancer. Another approach to targeting the immune system is by using monoclonal antibodies, which are engineered proteins that mimic the immune system's ability to recognize and neutralize viral particles. Monoclonal antibodies can be designed to target specific viral proteins or regions, preventing the virus from entering or exiting host cells. Monoclonal antibodies have been used to treat various viral infections, including Ebola, influenza, and COVID-19.
In addition to immunomodulatory agents and monoclonal antibodies, other approaches to targeting the immune system include immune checkpoint inhibitors and cytokine inhibitors. Immune checkpoint inhibitors block the signals that suppress the immune system, enhancing the immune response to viral infections. Cytokine inhibitors, such as tocilizumab, block the production of cytokines, which are proteins that regulate the immune response.
Another approach is to use immunomodulatory agents that can enhance the immune response to viral infections. These agents can help boost the production and function of immune cells, such as T cells and natural killer cells. Interferons are a group of immunomodulatory agents that have been used to treat various viral infections, including hepatitis B and C.
Monoclonal antibodies are another promising approach to targeting the immune system in viral infections. These antibodies are engineered proteins that can mimic the immune system's ability to recognize and neutralize viral particles [4,5]. Monoclonal antibodies can be designed to target specific viral proteins or regions, preventing the virus from entering or exiting host cells. In COVID-19, monoclonal antibodies have been shown to reduce hospitalization rates and improve outcomes in high-risk patients.
Emerging viral infections pose a significant public health threat worldwide. Antiviral agents are critical in treating and preventing the spread of these infections. These agents work by targeting the virus directly or indirectly by enhancing the host immune system to fight off the virus. In addition to targeting the virus directly, targeting the immune system is also critical in treating viral infections. Immunomodulatory agents, monoclonal antibodies, and other approaches can enhance the immune response to viral infections or prevent harmful effects from an overactive immune response.
Antiviral resistance and harmful immune responses are significant challenges in treating viral infections. Researchers are exploring new strategies for developing antiviral agents that can overcome resistance and prevent harmful immune responses. With continued research and development, we can better prepare ourselves to face the next emerging viral infection.
- Warren TK, Wells J. Protection against figovirus disesaee by a nove broad spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-5.
- Wang Z, Deisboeck TS. Mathematical modeling in cancer drug discovery. Drug discovery today. 2014; 19(2):145-150.
- Procko E, Berguig G. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell. 2014;157:1644-56.
- Neveu G, Ziv-Av A. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLOS pathogens. 2012;8: e1002845.
- Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating exisint metods n efficient pipelines. Drug discovery today. 2014;19(5):637-4.